Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

Company Pauses OV101 Program Based On NEPTUNE Results

nerve cells, concept for neurodegenerative and neurological disease — Ovid shifts focus after Phase III Angelman syndrome study disappoints. • Source: Shutterstock

Related Content

Pipeline Watch: Phase III Starts In Huntington's Disease, COVID-19, Head And Neck Cancer

Nov 03 2020

Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS

Aug 25 2020

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

Jul 13 2020

Related Companies

Ovid Therapeutics, Inc.

Angelini Labopharm LLC

GeneTx Biotherapeutics LLC

Ultragenyx Pharmaceutical Inc.

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Business Strategies Clinical Trials BioPharmaceutical Neurology

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window